A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region

British Journal of Dermatology

Volumn 142, Issue 6, 2000, Pages 1177-1183

  Baran, Robert ^d   Feuilhade, M ^a,b   Datry, A ^a,c   Goettmann, S ^a,d   Pietrini, P ^a,e   Viguie, C ^a,f   Badillet, G ^a,d   Larnier, C ^a,d   Czernielewski, J ^a,g  

^a NAIL DISEASE CENTRE   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d Cours Clémenceau ^*

^e Groupe Hospitalier Cochin ^*  (France)

^f Boulevard du Parc ^*  (France)

^g Leywood House   (United Kingdom)

Author keywords

Amorolfine; Onychomycosis; Terbinafine

Indexed keywords

AMOROLFINE; TERBINAFINE;

ADULT; ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DERMATOMYCOSIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENTIATION; FEMALE; HUMAN; MALE; MULTICENTER STUDY; ONYCHOMYCOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; NAPHTHALENES; ONYCHOMYCOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0344625748     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03545.x     Document Type: Article

References (25)

1. 1 Williams HC. The epidemiology of onychomycosis in Britain. Br J Dermatol 1993; 129: 101-9.
2. 2 Sais G. Jucglà A, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995; 132: 758-61.
3. 3 Heikkilä H. Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699-703.
4. 4 Ginter G, Rieger E, Heigl K, Propst E. Increasing frequency of onychomycoses - is there a change in the spectrum of infectious agents? Mycoses 1996; 39 (Suppl. 1): 118-22.
5. 5 Elewski BE, Hay RJ. Update on the management of onychomycosis: highlights of the third annual international summit on cutaneous antifungal therapy. Clin Infect Dis 1996; 23: 305-13.
6. 6 Balfour JA, Faulds D. Terbinafine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-84.
7. 7 Gupta AK, Scher RK, De Doncker P. Current management of onycomycosis: an overview. Dermatol Clin 1997; 15: 121-35.
8. 8 Van der Schroeff JC, Cirkel PKS, Crijns MB et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992; 126 (Suppl. 39): 36-9.
9. 9 Tausch I. Bräutigam M, Weidinger G, Jones TC. Lagos V Study Group. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. Br J Dermatol 1997; 136: 737-42.
10. 10 Baran R, De Doncker P. Lateral edge nail involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. (Letter.) Acta Derm Venereol (Stockh) 1996; 76: 82-3.
11. 11 Haria M, Bryson HM. Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995; 49: 103-20.
12. 12 Polak A. Combination of amorolfine with various antifungal drugs in dermatophytosis. Mycoses 1993; 36: 43-9.
13. 13 Frantz TJ. Absorption of amorolfine through human nail. Dermatology 1992; 184 (Suppl. 1): 18-20.
14. 14 Xaug M. Amorolfine nail lacquer: once-weekly application in onychomycosis. JAMA South East Asia 1993; 9 (Suppl. 4): 19-22.
15. 15 Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143-51.
16. 16 Arikian SR, Einarson TR, Kobelt-Nguyen G et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol 1994; 130 (Suppl. 43): 35-44.
17. 17 Marchetti A. Piech CT, McGhan AF et al Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18: 757-77.
18. 18 Tosti A, Piraccini BM, Stinchi C et al. Treatment of dermatophyte nail infection: an open randomized study comparing intermittent terbinafine therapy with continuous terbinafine treatment and intermittent itraconazole therapy. J Am Acad Dermatol 1996; 34: 595-600.
19. 19 Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 17 (Suppl. 1): 41-3.
20. 20 Reinel D, Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once weekly versus twice-weekly. Clin Exp Dermatol 1992; 17 (Suppl. 1): 44-9.
21. 21 Hofman H, Bräutigam M, Weidinger G et al. A randomized double-blind study with terbinafine and griseofulvin. Arch Dermatol 1995; 131: 919-22.
22. 22 Baran R, Hay R, Haneke E, Tosti A. eds. Onychomycosis, The Current Approach to Diagnosis and Therapy. London: Martin Dunitz, 1999; 41.
23. 23 Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol 1998; 134: 1551-4.
24. 24 Finlay AY. Pharmacokinetics of terbinafine in the nail. Br J Dermatol 1992; 126 (Suppl. 39): 28-32.
25. 25 Marty J-PL. Amorolfine nail lacquer: a novel formulation. J Eur Acad Dermatol Venereol 1995; 4S: 17-21.